M Gaspard - Concepedia

Author

M Gaspard

Also Known As

M GASPARD, M Gaspard, M H Gaspard, M. Gaspard, M. H. Gaspard, M.-H. Gaspard, M.H. Gaspard, M.‐H Gaspard, M.‐H. Gaspard, Marie-Hélène Gaspard

Publications

970

Citations

H-Index

Concepts

All Affiliations

Inserm Institut Paoli-Calmettes Centre Léon Bérard Sorbonne Université Hôpital de la Timone

About

M Gaspard is an author at Inserm specializing in medicine, immunology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	552
2	Health Sciences	3	3	120
3	Public Health	1	1	132
4	Allergy	1	1	12
5	Biomedical Engineering	1	1	14

M Gaspard

Publications

838

Citations

H-Index

Page 1

	Year	Citations
Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults M.L. Piel-Julian, Matthieu Mahévas, Johanne Germain, Journal of Thrombosis and Haemostasis Platelet Count ThresholdImmune Thrombocytopenia AdultsThrombosisHematologyPlatelet Concentrates	2018	132
Comparison of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukaemia in first remission: a prospective controlled trial Josy Reiffers, M Gaspard, D Maraninchi, British Journal of Haematology	1989	124
Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings Stefan Kubicka, Richard Greil, Thierry André, Annals of Oncology Gastrointestinal OncologyMedicinePathologyColorectal CancerMetastatic Colorectal Cancer	2013	101
Dihydropyrimidine dehydrogenase activity in cancer patients G. Milano, M Gaspard, A. Thyss, European Journal of Cancer Tumor BiologyOncologyAldehyde DehydrogenaseMedicineAnti-cancer Agent	1993	85
Renal tolerance of cisplatin in patients more than 80 years old. A. Thyss, Laurence Saudes, Jens Otto, Journal of Clinical Oncology	1994	64
Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies M Gaspard, D Maraninchi, Anne Marie Stoppa, Cancer Chemotherapy and Pharmacology Hematological MalignancyMarrow TransplantationMedicineMetronomic TherapyHematology	1988	56
Interleukin-2 and lymphokine-activated killer cells in 15 children with advanced metastatic neuroblastoma. Sylvie Négrier, Jean Michon, D. Floret, Journal of Clinical Oncology Cell TherapyLak CellsAdvanced Metastatic NeuroblastomaImmunologyPathology	1991	50
Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX Jean‐François Emile, Catherine Julié, Karine Le Malicot, European Journal of Cancer Prognostic BiomarkersGastrointestinal OncologyMedicineImmunologyColorectal Cancer	2017	45
Interleukin-2 with and without LAK cells in metastatic renal cell carcinoma: the Lyon first-year experience in 20 patients Thierry Philip, A. Mercatello, Sylvie Négrier, Cancer Treatment Reviews Lyon First-year ExperienceUrologyLak CellsGenitourinary CancerMalignant Disease	1989	34
Anti-LFA1 monoclonal antibody (25.3) for treatment of steroid-resistant grade III?IV acute graft-versus-host disease A.-M. Stoppa, D Maraninchi, Didier Blaise, Transplant International	1991	29

Page 1